These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38887849)

  • 1. Bioengineered Model of Human LGMD2B Skeletal Muscle Reveals Roles of Intracellular Calcium Overload in Contractile and Metabolic Dysfunction in Dysferlinopathy.
    Khodabukus A; Prabhu NK; Roberts T; Buldo M; Detwiler A; Fralish ZD; Kondash ME; Truskey GA; Koves TR; Bursac N
    Adv Sci (Weinh); 2024 Jun; ():e2400188. PubMed ID: 38887849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Sreetama SC; Chandra G; Van der Meulen JH; Ahmad MM; Suzuki P; Bhuvanendran S; Nagaraju K; Hoffman EP; Jaiswal JK
    Mol Ther; 2018 Sep; 26(9):2231-2242. PubMed ID: 30166241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice.
    White Z; Sun Z; Sauge E; Cox D; Donen G; Pechkovsky D; Straub V; Francis GA; Bernatchez P
    Skelet Muscle; 2022 Nov; 12(1):25. PubMed ID: 36447272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B.
    Bittel DC; Sreetama SC; Chandra G; Ziegler R; Nagaraju K; Van der Meulen JH; Jaiswal JK
    J Clin Invest; 2022 Jan; 132(1):. PubMed ID: 34981776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.
    Gushchina LV; Bhattacharya S; McElhanon KE; Choi JH; Manring H; Beck EX; Alloush J; Weisleder N
    Mol Ther; 2017 Oct; 25(10):2360-2371. PubMed ID: 28750735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysferlin protein analysis in limb-girdle muscular dystrophies.
    Vainzof M; Anderson LV; McNally EM; Davis DB; Faulkner G; Valle G; Moreira ES; Pavanello RC; Passos-Bueno MR; Zatz M
    J Mol Neurosci; 2001 Aug; 17(1):71-80. PubMed ID: 11665864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased nonHDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B.
    Sellers SL; Milad N; White Z; Pascoe C; Chan R; Payne GW; Seow C; Rossi F; Seidman MA; Bernatchez P
    J Lipid Res; 2018 Feb; 59(2):261-272. PubMed ID: 29175948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysferlin and animal models for dysferlinopathy.
    Kobayashi K; Izawa T; Kuwamura M; Yamate J
    J Toxicol Pathol; 2012 Jun; 25(2):135-47. PubMed ID: 22907980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysferlin at transverse tubules regulates Ca(2+) homeostasis in skeletal muscle.
    Kerr JP; Ward CW; Bloch RJ
    Front Physiol; 2014; 5():89. PubMed ID: 24639655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.
    White Z; Milad N; Tehrani AY; Chen WW; Donen G; Sellers SL; Bernatchez P
    PLoS One; 2019; 14(8):e0220903. PubMed ID: 31404091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound heterozygous DYSF variants causing limb-girdle muscular dystrophy type 2B in a Chinese family.
    Li L; Jing Z; Cheng L; Liu W; Wang H; Xu Y; Zheng X; Yu X; Liu S
    J Gene Med; 2020 Nov; 22(11):e3272. PubMed ID: 32889728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysferlinopathy: a clinical and histopathological study of 28 patients from India.
    Nalini A; Gayathri N
    Neurol India; 2008; 56(3):379-85; discussion 386-7. PubMed ID: 18974568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy.
    Patel NJ; Van Dyke KW; Espinoza LR
    Am J Med Sci; 2017 May; 353(5):484-491. PubMed ID: 28502335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s).
    Weiler T; Bashir R; Anderson LV; Davison K; Moss JA; Britton S; Nylen E; Keers S; Vafiadaki E; Greenberg CR; Bushby CR; Wrogemann K
    Hum Mol Genet; 1999 May; 8(5):871-7. PubMed ID: 10196377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies.
    Paradas C; Llauger J; Diaz-Manera J; Rojas-García R; De Luna N; Iturriaga C; Márquez C; Usón M; Hankiewicz K; Gallardo E; Illa I
    Neurology; 2010 Jul; 75(4):316-23. PubMed ID: 20574037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models.
    Vallecillo-Zúniga ML; Rathgeber MF; Poulson PD; Hayes S; Luddington JS; Gill HN; Teynor M; Kartchner BC; Valdoz J; Stowell C; Markham AR; Arthur C; Stowell S; Van Ry PM
    PLoS One; 2020; 15(9):e0238441. PubMed ID: 32881965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy.
    Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysferlin interacts with calsequestrin-1, myomesin-2 and dynein in human skeletal muscle.
    Flix B; de la Torre C; Castillo J; Casal C; Illa I; Gallardo E
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1927-38. PubMed ID: 23792176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.
    Nagaraju K; Rawat R; Veszelovszky E; Thapliyal R; Kesari A; Sparks S; Raben N; Plotz P; Hoffman EP
    Am J Pathol; 2008 Mar; 172(3):774-85. PubMed ID: 18276788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol absorption blocker ezetimibe prevents muscle wasting in severe dysferlin-deficient and mdx mice.
    White Z; Theret M; Milad N; Tung LW; Chen WW; Sirois MG; Rossi F; Bernatchez P
    J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):544-560. PubMed ID: 34927367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.